Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS MONTH'S ISSUE:
January 2015

Vortioxetine (Brintellix): a "Multi-Modal Antidepressant"
The new selective serotonin reuptake inhibitor (SSRI) antidepressant vortioxetine (Brintellix) offers no proven superiority in efficacy or tolerability over older, less expensive, and better tested agents.

Topiramate and Long-term Weight Loss in Schizophrenia Patients
For obese patients with schizophrenia, the anticonvulsant topiramate (Topamax) appears to promote weight loss during treatment and for long after it is discontinued.

In Brief
Paliperidone Palmitate (Invega Sustenna) Approved by FDA for Schizoaffective Disorder; Chronic Marijuana Use Causes Structural Changes in the Brain

Risks of Antipsychotic Drugs in Older Patients
Antipsychotic treatment in elderly patients is associated with an increased risk of mortality and may contribute to acute kidney injury.

About the BTP Newsletter

Our subscribers say BTP is…

"Very relevant, practical, and thought-provoking."

"About the only thing left without drug ads...objective and balanced."

"Succinct, readable, clear, timely and relevant!"

"Well written and scientifically sound."

Originating at the Massachusetts General Hospital and Harvard Medical School, Biological Therapies in Psychiatry has been a trusted resource for physicians for over 30 years. Described as "influential" by the Atlantic Monthly, this concise, four-page, monthly newsletter provides up-to-date information about the rapidly expanding field of psychotropic medications and other biological treatments for mental disorders.

From his perspective as an editor, teacher, investigator, and clinician, Alan J. Gelenberg, M.D., reviews the widespread literatures of science and clinical practice. Dr. Gelenberg distills the material most relevant for a busy practitioner and presents it each month with a balance of scientific curiosity, healthy skepticism, and clinical experience.

Dr. Gelenberg is Professor and Interim Chair of Psychiatry at Penn State, Hershey. Since 1987, Dr. Gelenberg has been Editor-in-Chief of the Journal of Clinical Psychiatry, and he recently chaired the workgroup that revised the American Psychiatric Association's major depressive disorder guidelines. Dr. Gelenberg has been on the faculty of Harvard Medical School, MIT, and the University of Arizona and has written numerous scientific articles and book chapters on mood disorders, depression, and schizophrenia. He is listed in the Best Doctors in America and America's Top Doctors and received the 1997 Exemplary Psychiatrist Award of the National Alliance for the Mentally Ill.

We offer both print and online subscriptions. Our web site provides subscribers with 24-hour access to archives as well as current issues. In addition, Continuing Medical Education credit is available for reading BTP. You can earn up to 12.0 hours in category 1 credit by answering questions in the December issue about topics covered during the year.